A phase 1 MAD/SAD study of Bremelanotide in hypothalamic obesity patients
Latest Information Update: 03 Apr 2025
At a glance
- Drugs Bremelanotide (Primary)
- Indications Obesity
- Focus Adverse reactions
- 03 Apr 2025 New trial record
- 31 Mar 2025 According to a Palatin Technologies media release, IND applications planned for 4Q25; clinical data expected 1H26